Bladder Cancer news from FierceBiotech
NewsALSO NOTED: Seattle Genetics to raise cash; Biocancell IIb trial approved;and much more...
> Seattle Genetics plans to raise cash by selling 10 million shares of its stock. Report > Read more...
ALSO NOTED: FDA says no to Indevus; Nektar gets sweetened deal with Baxter; Akela pulls public offering; and much more...
> Indevus Pharmaceuticals says that the FDA has turned thumbs down on its new therapy for bladder cancer, a move that trimmed its stock value. Valstar was pulled from the market five years ago Read more...
ALSO NOTED: BMS hands back drug rights; OncoMethylome in deal with GSK; Celgene shares take a bounce; and much more...
> Bristol-Myers Squibb has returned the rights to vinflunine to Pierre Fabre. The therapy was studied as a treatment for bladder cancer. Read more...
ALSO NOTED: Halozyme inks tech pact; Bioniche gains SPA; Ariad shares on rise; and much more...
> Halozyme Therapeutics has agreed to put its technology to work to develop a new formulation of Baxter's Gammagard Liquid for subcutaneous delivery. Gammagard is used to treat primary Read more...
| Press ReleasesPRESS RELEASE: Indevus Receives Approvable Letter From FDA for Valstar for Bladder Cancer TherapyIndevus Receives Approvable Letter From FDA for Valstar for Bladder Cancer Therapy LEXINGTON, Mass., Aug. 17 -- Indevus Pharmaceuticals, Inc. today announced that it has received an approvable letter Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets